Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sai Nudurupati

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinical and Experimental Gastroenterology|October 22, 2011
Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mgMichael Kukulka, Corey Eisenberg, Sai Nudurupati
Clinical and Experimental Gastroenterology|March 4, 2017
Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administrationMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Clinical and Experimental Gastroenterology|December 20, 2014
Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux diseaseMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Clinical and Experimental Gastroenterology|October 17, 2018
Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringeMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Therapeutic Advances in Gastroenterology|November 3, 2016
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsuleMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Therapeutic Advances in Gastroenterology|November 3, 2016
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazoleMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Electrophoresis|February 29, 2008
Concentrating particles on drop surfaces using external electric fieldsSai Nudurupati, Mohammad Janjua, Nadine Aubry, et al.
Drugs in R&D|November 7, 2014
Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal functionMichael Mayer, Sai Nudurupati, Xuejun Peng, et al.
Electrophoresis|February 23, 2011
Electric field-induced self-assembly of micro- and nanoparticles of various shapes at two-fluid interfacesMuhammad Janjua, Sai Nudurupati, Pushpendra Singh, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adultsRonald D Lee, Sai Nudurupati, John Marcinak, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical and Experimental Gastroenterology|October 22, 2011
Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mgMichael Kukulka, Corey Eisenberg, Sai Nudurupati
Clinical and Experimental Gastroenterology|March 4, 2017
Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administrationMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Clinical and Experimental Gastroenterology|December 20, 2014
Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux diseaseMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Clinical and Experimental Gastroenterology|October 17, 2018
Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringeMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Therapeutic Advances in Gastroenterology|November 3, 2016
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsuleMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Therapeutic Advances in Gastroenterology|November 3, 2016
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazoleMichael Kukulka, Sai Nudurupati, Maria Claudia Perez
Electrophoresis|February 29, 2008
Concentrating particles on drop surfaces using external electric fieldsSai Nudurupati, Mohammad Janjua, Nadine Aubry, et al.
Drugs in R&D|November 7, 2014
Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal functionMichael Mayer, Sai Nudurupati, Xuejun Peng, et al.
Electrophoresis|February 23, 2011
Electric field-induced self-assembly of micro- and nanoparticles of various shapes at two-fluid interfacesMuhammad Janjua, Sai Nudurupati, Pushpendra Singh, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adultsRonald D Lee, Sai Nudurupati, John Marcinak, et al.
Pageof 2